Lyra Therapeutics

Lyra Therapeutics

Lyra Therapeutics is a clinical-stage company developing medicines.

HQ location
Watertown, United States
Launch date
Employees
Market cap
$11.6m
Enterprise value
$14m
Share price
$7.05 LYRA
  • Edit
Get premium to view all results
DateInvestorsAmountRound
investor investor investor investor investor

€0.0

round
investor investor investor investor investor investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor investor investor investor investor investor investor

€0.0

round
N/A

€0.0

round
*
N/A

$5.0m

Post IPO Equity
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2021202220232024202520262027
Revenues0000000000000000000000000000
% growth-378 %14 %(2 %)(54 %)139 %777 %
EBITDA0000000000000000000000000000
% EBITDA margin(15304 %)(3938 %)(4086 %)(1607 %)---
Profit0000000000000000000000000000
% profit margin(15268 %)(4056 %)(4023 %)(6091 %)(4955 %)(3388 %)(381 %)
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue10419 %2846 %3083 %2853 %---

Source: Company filings or news article, Equity research estimates

Notes (0)
More about Lyra Therapeutics
Made with AI
Edit

Lyra Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. The company leverages its expertise in materials science, drug development, and formulation to create proprietary technology designed to deliver medicines directly, precisely, and consistently to the affected tissue for sustained periods with a single administration. Lyra Therapeutics' product candidates, LYR-210 and LYR-220, are bioabsorbable nasal implants intended to deliver up to six months of continuous mometasone furoate drug therapy through a brief, in-office procedure. The company's business model revolves around the development and commercialization of these specialized treatments, targeting patients suffering from CRS who cycle through various treatment options seeking lasting relief. Lyra Therapeutics operates in the biotechnology and pharmaceutical markets, primarily serving healthcare providers and patients dealing with CRS. The company generates revenue through the development, approval, and eventual sale of its proprietary drug delivery systems.

Keywords: chronic rhinosinusitis, biotechnology, drug delivery, nasal implants, bioabsorbable, mometasone furoate, materials science, clinical-stage, localized treatment, innovative therapies.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo